| Authors: |
Mina A; Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA., Xu Y; AbbVie, Inc., Chicago, IL, USA., Kapustyan TA; AbbVie, Inc., Chicago, IL, USA., Dhalla M; AbbVie, Inc., Chicago, IL, USA., Chen C; AbbVie, Inc., Chicago, IL, USA., Kamalakar R; AbbVie, Inc., Chicago, IL, USA., Lin CW; Genentech, Inc., South San Francisco, CA, USA., Ma E; Genentech, Inc., South San Francisco, CA, USA., Montez M; Genentech, Inc., South San Francisco, CA, USA., Wu Z; Genesis Research Group, Hoboken, NJ, USA., Yee T; Genesis Research Group, Hoboken, NJ, USA., Sun H; Genesis Research Group, Hoboken, NJ, USA., Rava A; Genesis Research Group, Hoboken, NJ, USA., Kim S; Genesis Research Group, Hoboken, NJ, USA., Huntington SF; Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA., Zeidan AM; Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA. |
